Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Selecting initial therapy for bladder cancer.

M S Soloway

    Cancer
    |August 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Effective intravesical therapies reduce recurrence for superficial bladder cancer. Neoadjuvant chemotherapy improves outcomes for locally advanced bladder cancer, potentially avoiding radical surgery.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Patient tolerability during office cystoscopy and bladder tumor cauterization: a multivariate analysis of risk factors.

    Actas urologicas espanolas·2022
    Same author

    Surveillance and office management of low-grade Ta bladder tumors.

    Actas urologicas espanolas·2022
    Same author

    Active surveillance for low-risk prostate cancer: knowledge, acceptance and practice among urologists.

    Prostate cancer and prostatic diseases·2011
    Same author

    Chemotherapy of experimental transitional-cell carcinoma.

    Urology·2011
    Same author

    Comparison of urologist reimbursement for managing patients with low-risk prostate cancer by active surveillance versus total prostatectomy.

    Prostate cancer and prostatic diseases·2010
    Same author

    Presentation and outcome following radical cystectomy in Hispanics with bladder cancer.

    International braz j urol : official journal of the Brazilian Society of Urology·2008
    Same journal

    Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

    Cancer·2026
    Same journal

    Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

    Cancer·2026
    Same journal

    EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

    Cancer·2026
    Same journal

    Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

    Cancer·2026
    Same journal

    Most older patients with advanced cancer prioritize QOL over extending survival: A secondary analysis of the GAP70+ trial found that among adults aged 70 and older with advanced, noncurable cancer, nearly three-quarters prioritized maintaining QOL.

    Cancer·2026
    Same journal

    Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer.

    Cancer·2026
    See all related articles

    Area of Science:

    • Uro-oncology
    • Medical treatment of bladder cancer
    • Cancer research

    Background:

    • Bladder cancer treatment has advanced for both early-stage and locally extensive disease.
    • Intravesical therapies are increasingly used for superficial tumors, reducing recurrence.
    • Neoadjuvant chemotherapy shows promise for locally advanced bladder cancer.

    Purpose of the Study:

    • To review current strategies for bladder cancer treatment.
    • To highlight the role of intravesical agents and neoadjuvant chemotherapy.
    • To discuss treatment decisions based on tumor stage and patient factors.

    Main Methods:

    • Endoscopic examination, tumor grading and staging.
    • Mucosal biopsies and cytology.
    • Intravesical therapy (mitomycin C, thiotepa, doxorubicin, bacillus Calmette-Guerin).

    Related Experiment Videos

  • Neoadjuvant chemotherapy for locally extensive disease.

    • Main Results:

    • Intravesical agents effectively treat and prevent recurrence of superficial bladder tumors.
    • Neoadjuvant chemotherapy achieves significant response rates in locally extensive bladder cancer.
    • Chemotherapy may downstage tumors, offering an alternative to radical surgery.

    Conclusions:

    • Treatment decisions integrate endoscopic findings, staging, and patient status.
    • Intravesical therapy is standard for non-muscle-invasive bladder cancer.
    • Neoadjuvant chemotherapy is a viable option for locally extensive bladder cancer, potentially improving cure rates.